AMENDMENTS TO THE CLAIMS

The following listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Previously Presented) A composition suitable for administration to a subject, said composition comprising a virus or a cell and a fusion polypeptide, said fusion polypeptide comprising

a first amino acid sequence which comprises a cell—surface binding moiety

and

a second amino acid sequence comprising a ligand for a cell surface polypeptide of a leukocyte,

wherein said composition includes said fusion polypeptide bound to said virus or said cell and includes said fusion polypeptide which is not bound to said virus or said cell, and wherein said fusion polypeptide is bound to a lipid on said virus or said cell by said cell—surface binding moiety.

2. (Previously Presented) The composition of claim 1, wherein said ligand of said second amino acid sequence is chosen from the group consisting of: a ligand for a cytokine receptor, a ligand for CD40, a ligand for an adhesion molecule, a ligand for a defensin receptor, a ligand for a heat shock protein receptor, a ligand for a T cell costimulatory molecule, a ligand for a counterreceptor for a T cell costimulatory molecule, a ligand for an opsonin receptor.

3. (Previously Presented) The composition of claim 2 wherein said ligand comprises at least five contiguous amino acids of a naturally occurring cytokine, said cytokine being chosen from the group: GM-CSF, an interleukin, a chemokine, an interferon, a TNF-alpha, a flt-3 ligand.

4. (Withdrawn – previously presented) The composition of claim 2 wherein said ligand comprises at least about five contiguous amino acids of a naturally occurring CD154 molecule.

5. (Previously Presented) The composition of claim 1, wherein said cell is chosen from the group consisting of: a tumor cell, a bacterial cell, a fungal cell, a cell of a parasite, a mammalian cell, an insect cell.

6. (Previously Presented) The composition of claim 5, wherein said cell is pathogenic.

7. (Previously Presented) The composition of claim 5, wherein said cell is attenuated.

8. (Currently Amended) The composition of claim 1, wherein said cell ~~is substantially unable to divide~~ divides at a rate that is less than about 50% of the rate of division of corresponding cells which are not treated to prevent cell division.

9. (Previously Presented) The composition of claim 1, wherein said leukocyte is an antigen presenting cell.

10. (Previously Presented) The composition of claim 9, wherein said leukocyte is a professional antigen presenting cell.

11. (Previously Presented) The composition of claim 9, wherein said leukocyte is a dendritic cell.

12. (New) The composition of claim 8, wherein said cell divides at a rate that is less than about 30-50% of the rate of division of corresponding cells which are not treated to prevent cell division.